Stoneridge, Inc. (SRI)

NYQ – Цена в реальном времени. Валюта: USD

7.34

+0.28 (3.97%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

7.36

+0.02 (0.27%)

После закрытия: Jun 26, 2026, 7:55 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Stoneridge, Inc. (SRI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoneridge, Inc. (SRI)

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Stoneridge, Inc. (SRI) Q1 2026 Earnings Call Transcript

Stoneridge Reports First Quarter 2026 Results

Stoneridge, Inc. to Broadcast its First Quarter 2026 Conference Call on the Web

Stoneridge's MirrorEye® Camera Monitor System Continues Strong Momentum, Achieving Record Global Sales and Production Milestones

Stoneridge Still Offers Excellent Growth Potential

Stoneridge, Inc. (SRI) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Stoneridge Reports First Quarter 2026 Results

Stoneridge's MirrorEye® Camera Monitor System Continues Strong Momentum, Achieving Record Global Sales and Production Milestones

Stoneridge Reports Fourth Quarter and Full-Year 2025 Results

Search stocks

Stoneridge, Inc. (SRI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoneridge, Inc. (SRI)

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Stoneridge, Inc. (SRI) Q1 2026 Earnings Call Transcript

Stoneridge Reports First Quarter 2026 Results

Stoneridge, Inc. to Broadcast its First Quarter 2026 Conference Call on the Web

Stoneridge's MirrorEye® Camera Monitor System Continues Strong Momentum, Achieving Record Global Sales and Production Milestones

Stoneridge Still Offers Excellent Growth Potential

Stoneridge, Inc. (SRI) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Stoneridge Reports First Quarter 2026 Results

Stoneridge's MirrorEye® Camera Monitor System Continues Strong Momentum, Achieving Record Global Sales and Production Milestones

Stoneridge Reports Fourth Quarter and Full-Year 2025 Results